PARAGON Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer

计划入组 469 人 · 首次发布于 2019 年 10 月 8 日

Post-market Follow Up Study on Paragon CRT® 100 (Paflufocon D)

计划入组 250 人 · 首次发布于 2019 年 12 月 5 日

Treatment of Alveolar Bone Defects Using Aastrom Biosciences Autologous Tissue Repair Cell Therapy

计划入组 24 人 · 首次发布于 2008 年 9 月 19 日

Biological isolate (United Paragon Associates)

Irinotecan-eluting beads

Glycopyranosyl lipid adjuvant (Revelation Biosciences)

PARAGON

Paragon 28

United States

PARAGON BIOTECK, INC.

United States

Emalex Biosciences Initiates Expanded Access Program for Novel Tourette Syndrome Therapy Ecopipam

Ligand Pharmaceuticals Leads $75M Royalty Financing for D-Fi Gene Therapy in Rare Skin Disease Trial

Harmony Biosciences Secures Patent Protection for WAKIX Through 2030 Settlement with Lupin